CervoMed Inc. — Director's Dealing 2016

May 20, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Diffusion Pharmaceuticals Inc. (DFFN)
CIK: 0001053691
Period of Report: 2016-05-16

Reporting Person: Kalergis David G (Director, Chairman and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-05-16	Stock Option (Right to Buy)	$0.96	A	204167	Acquired	2026-05-16	Common Stock (204167)	Direct

Footnotes

F1: The shares underlying the options vest in equal parts each month until fully vested on the third anniversary of the grant date.